Why the Cell Line Is the CMC Decision You Don’t Get to Undo – Part 2
Is your next blockbuster biologic doomed before your team even steps into a lab?
Why the Cell Line Is the CMC Decision You Don’t Get to Undo – Part 1
What if your blockbuster biologic stumbled—not because the science wasn’t there, but because no one asked if it could actually be manufactured at scale?
Why Your Dormant Omics Data Is Worth More Than the Data You’ll Generate Next – Part 2
What does it take to crack the code of protein production—and why do some proteins stubbornly refuse to cooperate, despite the best efforts of scientists and engineers?
Why Your Dormant Omics Data Is Worth More Than the Data You’ll Generate Next – Part 1
Somewhere in your lab, a hard drive is quietly storing omics data that hasn’t seen the light of day in years—genome sequences, metabolomics runs, scribbled notes in aging ELNs.
Detecting 1 in 100,000 Cells: DNA Barcoding for Smarter Clone Selection – Part 2
Cell line development in biotech is a race against time and complexity, with innovators constantly seeking solutions that provide robust and scalable data for manufacturability and regulatory demands.
Detecting 1 in 100,000 Cells: DNA Barcoding for Smarter Clone Selection – Part 1
Cloning workflows have long relied on brute force: screen more cells, automate harder, and hope that small-scale performance predicts manufacturability.
When Your Delivery Vehicle Contains a Membrane Protein: CMC Decisions With No Regulatory Precedent – Part 2
Biopharma faces mounting pressure to develop safer, more efficient platforms for delivering nucleic acid therapies, especially as regulatory agencies scrutinize novel formulations and excipients.
When Your Delivery Vehicle Contains a Membrane Protein: CMC Decisions With No Regulatory Precedent – Part 1
Imagine a delivery system that can slip straight into a cell’s membrane, bypassing the barriers that stop most genetic medicines in their tracks. While AAVs and lipid nanoparticles have charted the way for gene therapies, a new contender is emerging: proteolipid vehicles powered by viral fusion proteins.
Why Nanovesicles Outperform Exosomes: Scalable Drug Delivery Beyond Injectable Vaccines – Part 2
Manufacturing under GMP with no established playbook isn’t for the faint-hearted—especially when your therapeutic platform is first-in-class and the regulatory template hasn’t been written yet.
Why Nanovesicles Outperform Exosomes: Scalable Drug Delivery Beyond Injectable Vaccines – Part 1
What if the best way to unlock durable, broad-spectrum immunity is to rethink the very vessels delivering our vaccines?